Analytical Data
-
Gene name
PTGIR
- Application
-
Alternative Names
PTGI-R; IP1; PRIPR; Prostaglandin I2 Receptor; Prostanoid IP receptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43119
-
Expression Region
Arg296~Cys386
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGIR, or Prostaglandin I2 Receptor, is a critical G-protein coupled receptor (GPCR) that plays a significant role in various physiological processes, including vasodilation, inhibition of platelet aggregation, and modulation of inflammation. Understanding the structure and function of PTGIR is crucial for developing targeted therapies for cardiovascular diseases and other conditions associated with dysregulated prostaglandin signaling. The research surrounding PTGIR has intensified in recent years, particularly with the growing interest in GPCRs as therapeutic targets due to their involvement in numerous cellular responses. Recombinant PTGIR proteins have been expressed and purified to facilitate detailed biochemical and biophysical studies, allowing researchers to elucidate the receptor's signaling mechanisms and interactions with ligands, including its natural agonists, such as prostacyclin. These studies also seek to uncover the nuances of PTGIR's role in pathophysiological states, including atherosclerosis and hypertension, providing insights into potential drug development strategies. Additionally, advancements in molecular biology techniques have enabled the exploration of PTGIR's structure-function relationships, paving the way for innovative pharmacological interventions. Ultimately, the ongoing research on PTGIR recombinant proteins holds promise for improving our understanding of cardiovascular health and disease, offering avenues for novel therapeutic approaches.
